Monograph

M05BA04 - Alendronic Acid

Not porphyrinogenic

Rationale

Inorganic compound. Accumulates in bone tissue. Not metabolised. Two references consider it (probably) safe.

Chemical description

Aminophosphonate used in postmenopausal osteoporosis where it inhibits bone resorbtion. Selectively localized to resorbtion localities in the skeleton where it inhibits osteoclastic activity. Stored in bone tissue. South African list: use with care. French list: authorized. C.Andersson; patient reports: tolerated (n=1).

IPNet drug reports

Uneventful use reported in 16 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes M05B / M05BA or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames

Alendroninezuur · Bonasol · Fosamax

Alendronate · Fosamax

Acido Alendronico · Adelan · Alendrofarm · Binosto · Fosamax · Semandrol · Soludronate

Acido Alendronico · Adronat · Alendronato · Alendros · Alenic · Aston · Binosto · Bonasol · Doryx · Dralenos · Fosamax · Genalen · Glamor · Loss · Nofrattil · Osteum · Porodron · Poronal · Realen